- Original basic research
- Open Access
Correction of microplate location effects improves performance of the thrombin generation test
© Liang et al.; licensee BioMed Central Ltd. 2013
- Received: 8 February 2013
- Accepted: 11 May 2013
- Published: 5 July 2013
Microplate-based thrombin generation test (TGT) is widely used as clinical measure of global hemostatic potential and it becomes a useful tool for control of drug potency and quality by drug manufactures. However, the convenience of the microtiter plate technology can be deceiving: microplate assays are prone to location-based variability in different parts of the microtiter plate.
In this report, we evaluated the well-to-well consistency of the TGT variant specifically applied to the quantitative detection of the thrombogenic substances in the immune globulin product. We also studied the utility of previously described microplate layout designs in the TGT experiment.
Location of the sample on the microplate (location effect) contributes to the variability of TGT measurements. Use of manual pipetting techniques and applications of the TGT to the evaluation of procoagulant enzymatic substances are especially sensitive. The effects were not sensitive to temperature or choice of microplate reader. Smallest location effects were observed with automated dispenser-based calibrated thrombogram instrument. Even for an automated instrument, the use of calibration curve resulted in up to 30% bias in thrombogenic potency assignment.
Use of symmetrical version of the strip-plot layout was demonstrated to help to minimize location artifacts even under the worst-case conditions. Strip-plot layouts are required for quantitative thrombin-generation based bioassays used in the biotechnological field.
- Thrombin generation test
- Location effects
Thrombin generation test (TGT) measures kinetics of thrombin activity during coagulation of a blood plasma sample mixed with activators of blood coagulation . The TGT is widely used in clinical research to measure global hemostatic potential in blood coagulation disorders either for diagnostic purposes [2, 3] or as means of treatment monitoring [4, 5]. More recently, TGT became a useful tool in drug development and control of drug potency and quality in drug manufacture [6–9]. Although proposed in the 1950s , the test gained popularity only a decade ago after the technique was revolutionized with the introduction of fluorogenic thrombin substrates and microtiter plate reader format . However, the convenience of the microtiter plate technology can be deceiving: microtiter plate assays are prone to a special kind of variability caused by the uneven microenvironments in different wells of the plate .
In order to describe the location-based effects for the TGT assay, a recent biotechnology application of TGT was used. We and others found that the procoagulant activity of IVIG correlates with reported myocardial infarction, stroke and other thromboembolic events [12, 13]. Commercial (CAT® by Stago and Technothrombin® by Technoclone) as well as in house variants of the fluorogenic TGT method were especially helpful in identification of procoagulant IVIG lots by manufacturers and regulatory agencies[14, 15]. In this report, we describe how both in house and commercial methods are prone to location-based biases which can be addressed with the use of symmetrical strip-plot layout design.
Human normal pooled plasma (FACT) was from George King Biomedicals. Immunodepleted Factor XI deficient plasma was from Affinity Biologicals (Ontario, Canada). Human plasma-derived Factor XIa was from Haematologic Technologies Inc (Essex Junction, VT). Recombinant lipidated tissue factor (rTF, Dade Innovin) was from Dade Behring (Marburg, Germany). TF activity was determined using the Actichrome TF chromogenic kit (American Diagnostica). Fluorogenic substrate for thrombin Z-Gly-Gly-Arg-AMC was from Bachem (Torrance, CA). Phospholipid vesicles were from Technoclone (Diapharma, West Chester, OH). The Thrombin Calibrator and TF reagent PPP-low used in the CAT instrument experiment were from Thrombinoscope BV, Maastricht, The Netherlands.
In house thrombin generation test for IVIG procoagulant activity
Thrombin generation was measured as described in [8, 16, 17]. Thrombin generation profiles in FXI-deficient or normal plasma (75% by reaction volume) supplemented with fluorogenic substrate Z-Gly-Gly-Arg-AMC (800 μM) and phospholipids vesicles (4 μM) were mixed with serially diluted thrombogenic lot of IVIG or FXIa. To reduce procedural errors, all reagents and plates were kept on plate heater (37°C); plasma was mixed with substrate and lipids prior transfer to microtiter wells; IVIG and FXIa samples (20% by reaction volume) were transferred to plasma using a 12- or 8-channel pipette, and reaction was started by rapidly adding 2.54 μL (2.5% by reaction volume) of a mixture containing tissue factor (0.3 pM) and CaCl2 (20 mM) using another 12-channel pipette. Recording was conducted in two microplate readers, Infinite F500 (Tecan, Durham, NC) and Synergy H4 (Biotek, Winooski, VT) at 37°C.
TG curve processing software
In house assay data processing was performed using an automated software package designed by Dr. Mikhail Ovanesov using OriginPro (OriginLab, Northampton, MA; the package is available from us upon request). The software is capable of applying different processing algorithms during the conversion of raw fluorescence to the processed TG curve, and computes the final TG curve parameters. The software can also apply the thrombin calibration and thrombin-α2macroglobulin (α2MG) correction algorithms . For quantitative assessment of IVIG procoagulant activity (a bioassay approach ), a calibration curve was prepared from a serially diluted IVIG standard or FXIa. Thrombin peak height (TPH) values were plotted against FXIa concentration and fitted with a cubic polynomial equation. To calculate FXIa activity in the well, the calibration curve was applied to the TPH and multiplied by the pre-dilution of the sample in the well.
Commercial thrombin generation test (CAT)
IVIG samples were mixed with plasma as described in the in house method, but after that the experiment was performed and processed according to the manufacturer’s guidelines using CAT microplate reader and software package (Diagnostica Stago, Inc., Parsippany, NJ).
Row-dependent location artifacts of TGT
However, we found that TG in duplicate wells containing the same IVIG sample can differ in a non-random systematical manner by up to 50% if the wells are located on separate rows of the plate. This can be illustrated by progressively reduced and delayed TG of “row control” samples on rows A through H (Figure 1B). Since lag time and time to thrombin peak were affected greater than the TPH by this systematic error, we chose TPH as the primary measure of IVIG procoagulant activity.
Analysis of multiple TGT microplate experiments presented in Figure 1C demonstrates statistically significant trends between upper and lower rows of the microplate under variety of conditions. Similar trends were observed for two IVIG samples (Figure 1C, compare black and light gray bars). Normal plasma (white bars) was less sensitive to this trend which correlates well with lower sensitivity of normal plasma to procoagulant activity under the conditions of this experiment (data not shown). Interestingly, when the order of row recalcification was reversed from A ➔ H to H ➔ A, the trend was also reversed (Figure 1C, compare black and dark gray bars).
Effect of temperature
Previous investigations demonstrated that reduced temperature of plasma sample prior to placement of the microplate into the reader may lead to increased thrombin generation . However, the role of temperature in the observed row-to-row artifacts was ruled out in our experiments. We kept our plasma and microplates on heat plates (three different brands of heaters used) and used pre-warmed pipet tips and microplate readers. The temperature of plasma wells on the heater before, after recalcification and after readings in the microplate reader was the same as assessed by an infra-red thermometer (0.1°C resolution).
Row effect on IVIG samples with different procoagulant activities
Row effects for FXIa on different microplate reader instruments
Correction of row-to-row artifacts with symmetrical duplicate well averaging
Row effects in a commercial TGT
Importance of row effect correction for quantitative bioassay
The clinical laboratory version of the TGT is usually intended for comparison of coagulation potentials of patient and healthy donor plasma samples [2, 3] or patient-specific evaluation of the procoagulant and anti-coagulant effects of existing and investigational treatments [4, 5]. Consequently, prior research on TGT assay development largely focused on preanalytical conditions and proper calibration of assay in units of thrombin activity. Improved quality of collected blood plasma samples, control of plasma temperature as well as internal thrombin calibration or normalization on standard plasma sample were shown to improve assay performance.
Evaluation of drug efficacy and quality, unlike clinical applications, may be less sensitive to preanalytical conditions because several drug preparations are compared with each other on the same microplate using a single sample of plasma. However, quantitative assessment of the difference between drug preparations usually requires comparison of different drug doses. Ideally, a bioassay is employed in which comparison to a standard drug preparation employs a calibration curve or a parallel line assay. Therefore, biotechnology applications require additional TGT qualification to ensure consistent low limit of detection, linear dose-response range and parallelism of tested and standard drugs.
Randomization of samples is an effective solution to correct location effects in high throughput analytical assays, but complete randomization of sample layout on the microtiter plate is prone to procedural errors . A more practical approach is a strip-plot design in which samples are assigned to random columns and serial dilutions of each sample to one column . However, in a typical TGT experiment, more samples are tested than there are columns on a plate, and the number of serial dilutions is smaller than there are rows. Since all coagulation samples are tested at least in duplicates, we propose to use a symmetrical design in which duplicates are positioned symmetrically with respect to the center of the plate. When applied to IVIG-TGT, this approach corrects the row-to-row drift and is easy to implement: (a) prior to addition to plasma, double volumes of IVIG samples are arranged in columns 1 through 6 (half of the plate), each sample in a single well, dilutions arranged vertically, (b) plasma is mixed with other required reagents (e.g., lipids) and transferred to cover all 96 wells of another plate, (c) IVIG samples are transferred to columns 1 through 6 of the plasma plate, (d) the plasma plate is then rotated 180° degrees, and (e) step c is repeated.
While we encountered location errors during drug screening studies, these findings may be even more important for other TGT applications, e.g., use of TGT for diagnosis and treatment of patients . Sensitivity of coagulation assays to pre-analytical conditions has been known for decades yet the causes of TGT variability have only recently been investigated , but location artifacts were not discussed in the literature. Location effect can be introduced in various ways. We found that if a coagulation enzyme, e.g., FXIa or FVIIa, is added manually to multiple wells on a microtiter plate, a well-to-well drift appears due to the different durations of contact between the enzyme and plasma inhibitors. A similar effect may be observed if TF or contact activator is added manually before recalicification. In our experience, long exposure of plasma to fluorogenic substrate prior to recalcification also decreases the TGT response. Edge effects can be caused by uneven heating of microplate inside the reader and artifacts of liquid dispenser. It should be noted that internal normalization on the thrombin-α2macroglobulin activity calibrator (e.g., as proposed by Hemker et al. ) is not helpful here because the thrombin calibrator only corrects for fluorogenic signal-related inaccuracies and fails to correct for biological and pipetting variables . All location effects may be corrected with the use of the strip-plot sample design. Specifically, when edge artifacts are minor, our symmetrical strip-plot design provides the simplest practical solution for microplate-based TGT experiments.
The authors are employees of the U.S. Food and Drug Administration. The findings and conclusions in this presentation have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.
- Van Geffen M, Van Heerde WL: Global haemostasis assays, from bench to bedside. Thromb Res. 2012, 129: 681-687. 10.1016/j.thromres.2011.12.006.View ArticlePubMedGoogle Scholar
- Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S: The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost. 2000, 83: 589-591.PubMedGoogle Scholar
- Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S, Hemker HC: The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002, 88: 576-582.PubMedGoogle Scholar
- Salvagno GL, Berntorp E: Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. Semin Thromb Hemost. 2010, 36: 780-790. 10.1055/s-0030-1265295.View ArticlePubMedGoogle Scholar
- Dargaud Y, Lienhart A, Negrier C: Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010, 116: 5734-5737. 10.1182/blood-2010-06-291906.View ArticlePubMedGoogle Scholar
- Butenas S, Parhami-Seren B, Gissel MT, Gomperts ED, Fass DN, Mann KG: Potency and mass of factor VIII in FVIII products. Haemophilia. 2009, 15: 63-72. 10.1111/j.1365-2516.2008.01826.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP: Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003, 33: 16-22. 10.1159/000071637.View ArticlePubMedGoogle Scholar
- Nagashima H: Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002, 277: 50439-50444. 10.1074/jbc.M208222200.View ArticlePubMedGoogle Scholar
- Bunce MW, Toso R, Camire RM: Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood. 2011, 117: 290-298. 10.1182/blood-2010-08-300756.PubMed CentralView ArticlePubMedGoogle Scholar
- Macfarlane RG, Biggs R: A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol. 1953, 6: 3-8. 10.1136/jcp.6.1.3.PubMed CentralView ArticlePubMedGoogle Scholar
- Harrison RO, Hammock BD: Location dependent biases in automatic 96-well microplate readers. J Assoc Off Anal Chem. 1988, 71: 981-987.PubMedGoogle Scholar
- Ovanesov MV, Shibeko AM, Woodle SA, Anderson CM, Hogwood J, Barson H, Gray E, Scott D: Association of Factor XIa with Intravenous Immune Globulin Products Implicated in Thrombotic Adverse Events: Biochemical Root Cause Investigation. J Thromb Haemost. 2011, 9: 272-O-TU-039Google Scholar
- Roemisch JR, Kaar W, Zoechling A, Kannicht C, Putz M, Kohla G, Schulz P, Pock K, Huber S, Fuchs S, et al: Identification of Activated FXI as the Major Biochemical Root Cause in IVIG Batches Associated with Thromboembolic Events Analytical and Experimental Approaches Resulting in Corrective and Preventive Measures Implemented into the Octagam® Manufacturing Process. Webmed Central Immunotherapy. 2011, 2: WMC002002-Google Scholar
- FDA Public Workshop “Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products”. May 17-18. 2011, [http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM258022.pdf], . Meeting transcript
- Gray E, Wilmot H, Hogwood J, Rigsby P: Evaluation of the proposed WHO 1st Reference Reagent for Activated Blood Coagulation Factor XI (FXIa), Human. [http://www.who.int/biologicals/expert_committee/BS_2206_1st_Reference_Reagent_FactorXIa.pdf] 2012. 5-7-2013
- Ovanesov MV, Ananyeva NM, Panteleev MA, Ataullakhanov FI, Saenko EL: Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. J Thromb Haemost. 2005, 3: 321-331. 10.1111/j.1538-7836.2005.01128.x.View ArticlePubMedGoogle Scholar
- Shibeko AM, Woodle SA, Lee TK, Ovanesov MV: Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood. 2012, 120: 891-899. 10.1182/blood-2011-11-393371.PubMed CentralView ArticlePubMedGoogle Scholar
- Ovanesov MV: Laboratory Investigations of products associated with thrombotic events. FDA/PPTA/HHA Workshop on “Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products, May 17-18, 2011 (Rockville, MD). 2011, [http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM260788.pdf], (Rockville, MD)
- De Smedt E, Hemker HC: Thrombin generation is extremely sensitive to preheating conditions. J Thromb Haemost. 2011, 9: 233-234. 10.1111/j.1538-7836.2010.04136.x.View ArticlePubMedGoogle Scholar
- Lansky D: Strip-plot designs, mixed models, and comparisons between linear and non-linear models for microtitre plate bioassays. Dev Biol (Basel). 2002, 107: 11-23.Google Scholar
- Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wagenvoord R, Lecompte T, Beguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003, 33: 4-15. 10.1159/000071636.View ArticlePubMedGoogle Scholar
- Van Berkel SS, Van der Lee B, Van Delft FL, Wagenvoord R, Hemker HC, Rutjes FP: Fluorogenic peptide-based substrates for monitoring thrombin activity. Chem Med Chem. 2012, 7: 606-617.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.